Results 251 to 260 of about 5,269,973 (298)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2004
Fragment-based lead discovery is gaining momentum in both large pharmaceutical companies and biotechnology laboratories as a complementary approach to traditional screening. This is because fragment-based approaches require significantly fewer compounds to be screened and synthesized, and are showing a high success rate in generating chemical series ...
David Charles Rees +2 more
exaly +3 more sources
Fragment-based lead discovery is gaining momentum in both large pharmaceutical companies and biotechnology laboratories as a complementary approach to traditional screening. This is because fragment-based approaches require significantly fewer compounds to be screened and synthesized, and are showing a high success rate in generating chemical series ...
David Charles Rees +2 more
exaly +3 more sources
Lead Discovery Using Molecular Docking
Current Opinion in Chemical Biology, 2002As the structures of more and more proteins and nucleic acids become available, molecular docking is increasingly considered for lead discovery. Recent studies consider the hit-rate enhancement of docking screens and the accuracy of docking structure predictions. As more structures are determined experimentally, docking against homology-modeled targets
John J Irwin, Brian K. Shoichet
exaly +3 more sources
The in Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
Current Medicinal Chemistry, 2019Background:Discovery and development of a new drug is a long lasting and expensive journey that takes around 20 years from starting idea to approval and marketing of new medication. Despite R&D expenditures have been constantly increasing in the last few years, the number of new drugs introduced into market has been steadily declining.
Marco Radi +2 more
exaly +4 more sources
Microdosing in Early Lead Discovery
Bioanalysis, 2010Microdosing provides a tool to enhance drug development by initiating human studies prior to Phase I studies. The purpose is to assist in the go versus no-go decision-making process and to eliminate early ineffective compounds from the drug pipeline. Selection of multiple potential leads can be performed at the clinical stage instead of in preclinical ...
Jekunen, A.P. +2 more
openaire +3 more sources
Fragment-based lead discovery: leads by design
Drug Discovery Today, 2005Fragment-based lead discovery (also referred to as needles, shapes, binding elements, seed templates or scaffolds) is a new lead discovery approach in which much lower molecular weight (120-250 Da) compounds are screened relative to HTS campaigns. Fragment-based hits are typically weak inhibitors (10 microM-mM), and therefore need to be screened at ...
Robin A E, Carr +3 more
openaire +2 more sources
Molecular Modeling in the Discovery of Drug Leads
Journal of Chemical Information and Computer Sciences, 1996The National Cancer Institute of the U.S.A. maintains a repository of about 500,000 chemicals which it has tested at some time for anticancer activity. As new chemotherapeutic targets present themselves, methods have been developed by which this large database can be re-examined without resorting to expensive high-volume biological screening ...
George W. A. Milne +2 more
openaire +2 more sources
Fragment-Based Lead Discovery and Design
Journal of Chemical Information and Modeling, 2014Fragment-based lead discovery and design has and continues to show increasing promise in drug discovery. In this article, the current state of the art in terms of hot-spot characterization, fragment screening techniques, and fragment-based design is discussed. Three overall fragment-based lead generation strategies are explored and involve the chemical
Diane Joseph-McCarthy +3 more
openaire +2 more sources
Virtual Screening for Lead Discovery
2011The identification of small drug-like compounds that selectively inhibit the function of biological targets has historically been a major focus in the pharmaceutical industry, and in recent years, has generated much interest in academia as well. Drug-like compounds are valuable as chemical genetics tools to probe biological pathways in a reversible ...
Yat T, Tang, Garland R, Marshall
openaire +2 more sources
Knowledge-Driven Lead Discovery
Mini-Reviews in Medicinal Chemistry, 2005Virtual screening encompasses several computational approaches which have proven valuable for identifying novel leads. These approaches rely on available information. Herein, we review recent successful applications of virtual screening. The extension of virtual screening methodologies to target families is also briefly discussed.
openaire +2 more sources
Thermodynamics guided lead discovery and optimization
Drug Discovery Today, 2010The documented unfavorable changes of physicochemical properties during lead discovery and optimization prompted us to investigate the present practice of medicinal chemistry optimization from a thermodynamic perspective. Basic principles of binding thermodynamics suggest that discriminating between enthalpy-driven and entropy-driven optimizations ...
György G, Ferenczy, György M, Keserũ
openaire +2 more sources

